New twelve-month data for Nevo stent
At 12 months the NEVO Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus Liberte according to new data presented today from the NEVO RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular…

















